Brought to you by 
Rigel partners TGF beta inhibitors with Bristol
01 Feb 2023
Executive Summary
Concurrent with its acquisition of Flexus Biosciences Inc. and related immune checkpoint assets, Bristol-Myers Squibb Co. signed a deal with Rigel Pharmaceuticals Inc. also in immuno-oncology. BMS received exclusive worldwide rights to Rigel's preclinical transforming growth factor (TGF) beta receptor kinase inhibitors.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Rigel partners TGF beta inhibitors with Bristol
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice